Illimis Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$42M
- Investors
-
27
Illimis Therapeutics General Information
Description
Developer of protein-based therapeutics designed for the treatment of intractable neurodegenerative diseases. The company's platform leverages proprietary protein engineering and molecular design techniques, enabling the biopharmaceutical companies to increase drug candidates with target specificity and improved stability.
Contact Information
Website
www.illimistx.comCorporate Office
- 2nd and 3rd floors, 18, Heonreung-ro 569-gil, Segok-dong, Unseong Building
- Gangnam-gu
- Seoul, 06376
- South Korea
Corporate Office
- 2nd and 3rd floors, 18, Heonreung-ro 569-gil, Segok-dong, Unseong Building
- Gangnam-gu
- Seoul, 06376
- South Korea
Illimis Therapeutics Timeline
Illimis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series B) | 02-Jul-2025 | $42M | Completed | Pre-Clinical Trials | ||
| 4. Accelerator/Incubator | 17-Oct-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 05-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Oct-2021 | $6.97M | Completed | Startup | ||
| 1. Seed Round | 09-Aug-2021 | $6.97M | $6.97M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Illimis Therapeutics Signals
Illimis Therapeutics Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| A Ventures | Venture Capital | Minority | ||
| Comes Investment | Venture Capital | Minority | ||
| Hana Ventures | Corporate Venture Capital | Minority | ||
| IMM Investment | Asset Manager | Minority | ||
| Industrial Bank of Korea | PE/Buyout | Minority |
Illimis Therapeutics FAQs
-
When was Illimis Therapeutics founded?
Illimis Therapeutics was founded in 2021.
-
Where is Illimis Therapeutics headquartered?
Illimis Therapeutics is headquartered in Seoul, South Korea.
-
What is the size of Illimis Therapeutics?
Illimis Therapeutics has 40 total employees.
-
What industry is Illimis Therapeutics in?
Illimis Therapeutics’s primary industry is Drug Discovery.
-
Is Illimis Therapeutics a private or public company?
Illimis Therapeutics is a Private company.
-
What is Illimis Therapeutics’s current revenue?
The current revenue for Illimis Therapeutics is .
-
How much funding has Illimis Therapeutics raised over time?
Illimis Therapeutics has raised $64.3M.
-
Who are Illimis Therapeutics’s investors?
A Ventures, Comes Investment, Hana Ventures, IMM Investment, and Industrial Bank of Korea are 5 of 27 investors who have invested in Illimis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process